📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Référence presse grand public
Cité 4 fois dans les médias — pédagogie reconnue
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Le Berry Républicain · 25/10/2016
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxNcWJXVXNJUHpTbTFBQ09LUVJGM2VBSXRMOVFQWUlOQVc4ZDhfcEdQWGRtZDRMMVgzSlBNN2p6d2ZXNkQ5Nk9NX3RaZlNkbUxwSDdaTUJTbC1OVUN0YlZFR3QtUjR3eEZlamVTSDBoRFJoV1F4Z2x0SjQ4eDVWM2dpczJ4UWg5SmR4cjlaOURJeU9sMFZYaHpFekxvRVlqZ0I4VzZma0dYRklzczkzMjNieDVIQmdidUFQal
📰 Le Berry Républicain · 19/10/2013
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxQUm8tbG1pNmNaZDBicWZzeFpsUDFXYlg0WjRkbjROSUY4TGx2djdjbE5SZElqaExfXzBYcmRfYlJjR1FvRkxIMWpnSnl0UVd1QWg2REdpVlI1TmhJNUtiY0Uzc0tkeHFYbjNWTlpQbnI4V0hCeVhfYjgzcmZrS2YyaDhQb0NKc2loRDNSd2ZpZDF0ZXJiZ1JjVTFwUnJhRi1pbjBMaHZ3NHNhTkdtZXRMX3drTks3T0Nrbn
📰 Le Berry Républicain · 04/09/2013
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxQZ2JMWUthOFVjakIwTG5FNXVYVU5CTGhPY3JlUFoxRGNKTG94MEd2MGZwak5tQzVhZV9VTWhfcDEyaE9NWm5zU05xeVU4LWVXMzA5WXhQZTY5eGNQcEhjcWdwVDlEMTlReG83bGwyZ1dGWlIyNThJRG1ZX0JtaFdodEVVVFN4S1lBNEZYeFRGMENUQnQ2YXR6a09zaEVwQTRjU3E1bkFCRzF1QXoyNTFDbWNxZTdWei1NYV
📰 Le Berry Républicain · 13/12/2012
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPMFZLeEprX2NyT0thTGdRYXJaMGJpUkFvWUs1UHpyaS1GeDNrSkViU3pjSEU3RG50YVFLRDZTSDRPeElrR1d4WUlPTk56VHd2OUNTY29WY2Fya3VfU1pLSjdfcDNLNmtCRW5uSUFGQm9kbjl0WE1TQ1dqSXRybnpjSXVKTjhZZjVVVzlMcHRSODBfcFNrYkpEQUpn?oc=5" target="_blank">Un nouveau centre d
RMD open · 2020
Objective To characterise changes in selected haematological parameters following once-daily oral baricitinib dosing. Methods Data were pooled from eight randomised clinical trials (four phase 3, three phase 2, one phase 1b) and one long-term extension. Changes in haematological parameters were evaluated up to 128 weeks (N=2387); overall safety of baricitinib was assessed up to 6 years (N=3492). Results Mean absolute neutrophil counts decreased (−1.36×109/L) within 1 month, followed by stabilisation within the normal reference range through week 128. The incidence of serious infections was not elevated in patients with neutropenia during the 24-week placebo-controlled period. Mean lymphocyte counts increased (+0.30×109/L) within 1 month, then decreased to baseline (weeks 12–24). Mean platelet counts increased at week 2 (+51×109/L), then decreased towards baseline. Overall, mean haemoglobin concentrations decreased (−0.12 mmol/L), then returned to baseline; however, reduced baseline haemoglobin concentrations observed in the highest baseline high-sensitivity C reactive protein quartile increased over time. Permanent drug discontinuation occurred due to laboratory abnormalities related to neutrophil count in 8 (0.2%), lymphocyte counts in 6 (0.2%), platelet counts in 8 (0.2%), and haemoglobin levels in 16 (0.5%) of all baricitinib-treated patients (N=3492 with 7993 total person-years of exposure). Conclusions Moderate decreases in neutrophils were seen during baricitinib treatment; however, serious infection was uncommon in patients with neutropenia. Transient increases were observed in lymphocytes and platelets, which returned to baseline over time. Changes in haemoglobin concentration were generally small. Haematological abnormalities seldom led to drug discontinuation.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
RMD open · 2020 · Journal Article
Kay J, Harigai M, Rancourt J, Dickson C, et al.